Skip to content

13F-HR filed by Cormorant Asset Management, LP

Cormorant Asset Management, LP filed this 13F-HR for the quarter ended 2025-09-30, filed 2025-11-14, with 36 holding rows worth $1,449,259,159.

Accession
0001583977-25-000011
Filed
2025-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2025

A holdings report, 36 entries on the cover page, a total value of $1,449,259,159 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,449,259,159 with VALUE read as dollars as filed, 13F file number 028-15949. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BRIDGEBIO ONCOLOGY THERAPEUT107924102COM NEW17,878,594$207,034,119dollars as filed
ABIVAX SA-00370M103SPONSORED ADS1,950,000$165,555,000dollars as filed
EYEPOINT INC COM NEW30233G209Stock8,325,000$118,548,000dollars as filed
RAPPORT THERAPEUTICS INC COM75383L102Stock3,192,521$94,817,874dollars as filed
BRIDGEBIO PHARMA INC10806X102COM1,400,000$72,716,000dollars as filed
EDGEWISE THERAPEUTICS INC28036F105COM4,010,000$65,042,200dollars as filed
BRIGHT MINDS BIOSCIENCES INC10919W405COMMON STOCK1,059,331$64,259,018dollars as filed
ARCELLX INC COMMON STOCK03940C100Stock775,000$63,627,500dollars as filed
INSMED INC COM PAR $.01457669307Stock430,000$61,924,300dollars as filed
NEWAMSTERDAM PHARMA CO NVN62509109COMMON STOCK2,175,000$61,857,000dollars as filed
PRAXIS PRECISION MEDICINES I74006W207COM NEW1,000,000$53,000,000dollars as filed
CENTESSA PHARMACEUTICALS PLC152309100SPONSORED ADS1,925,000$46,681,250dollars as filed
PHARVARIS NVN69605108COMMON STOCK1,363,200$34,011,840dollars as filed
CORBUS PHARMACEUTICALS21833P301COM NEW2,375,000$30,043,750dollars as filed
GH RESEARCH PLC ORDINARY SHARESG3855L106Stock1,916,439$27,405,078dollars as filed
CG ONCOLOGY INC156944100COMMON STOCK625,000$25,175,000dollars as filed
KORRO BIO INC500946108COMMON STOCK465,000$22,268,850dollars as filed
MBX BIOSCIENCES INC COM55287L101Stock1,225,000$21,437,500dollars as filed
METSERA INC59267L107COM400,000$20,932,000dollars as filed
JANUX THERAPEUTICS INC47103J105COM850,000$20,774,000dollars as filed
TARSUS PHARMACEUTICALS INC87650L103COMMON STOCK300,000$17,829,000dollars as filed
CRINETICS PHARMACEUTICALS INC COM22663K107Stock400,000$16,660,000dollars as filed
ENGENE HOLDINGS INC29286M105COM2,323,595$15,870,154dollars as filed
ARCUTIS BIOTHERAPEUTICS INC03969K108COM775,000$14,608,750dollars as filed
MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD61559X104Stock1,994,173$14,298,220dollars as filed
AVIDITY BIOSCIENCES INC COM05370A108Stock300,000$13,071,000dollars as filed
BIOAGE LABS INC COM09077V100Stock2,140,605$12,586,757dollars as filed
AXSOME THERAPEUTICS INC. COM05464T104Stock100,000$12,145,000dollars as filed
CABALETTA BIO INC12674W109COMMON STOCK5,000,000$11,700,000dollars as filed
ORUKA THERAPEUTICS INC COM687604108Stock533,340$10,256,128dollars as filed
ALUMIS INC022307102COM2,147,396$8,568,110dollars as filed
BIOMEA FUSION INC09077A106CMN3,570,872$7,213,161dollars as filed
AMYLYX PHARMACEUTICALS INC03237H101COM500,000$6,795,000dollars as filed
VAXCYTE INC COM92243G108Stock175,000$6,303,500dollars as filed
ENLIVEN THERAPEUTICS INC COM29337E102Stock200,000$4,094,000dollars as filed
BIOHAVEN LTDG1110E107COM10,000$150,100dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001583977-25-000011this filing2025-11-14acceptance time not in the bulk data set